Giuseppe Bertuglia
A5047707382- Multiple Myeloma Research and Treatments
- Protein Degradation and Inhibitors
- Peptidase Inhibition and Analysis
- Cancer Mechanisms and Therapy
- Cancer Treatment and Pharmacology
- Chronic Lymphocytic Leukemia Research
- Chronic Myeloid Leukemia Treatments
- Histone Deacetylase Inhibitors Research
- HIV/AIDS drug development and treatment
- Chemokine receptors and signaling
- Peripheral Neuropathies and Disorders
- Research on Leishmaniasis Studies
- Cancer Research and Treatment
- Immunotherapy and Immune Responses
- Computational Drug Discovery Methods
- Hematopoietic Stem Cell Transplantation
- Phytochemical compounds biological activities
- Autoimmune and Inflammatory Disorders
- Trypanosoma species research and implications
- Histiocytic Disorders and Treatments
Azienda Ospedaliera Citta' della Salute e della Scienza di Torino
2022-2025
University of Turin
2022-2024
ABSTRACT This multicenter real‐world analysis evaluated the efficacy of isatuximab, pomalidomide, and dexamethasone (IsaPd) in 51 patients with multiple myeloma (MM) who were refractory to daratumumab (Dara‐R). The majority under 70 years old (60.8%), predominantly female (56.9%), heavily pretreated, 74.5% being triple‐class (TCR); 32.1% 28 cytogenetic data had high‐risk abnormalities. overall response rate (ORR) was 56.9%, including 3 stringent complete (sCR), 4 CR, 7 very good partial...
Not available.
In the ELOQUENT-3 trial, combination of elotuzumab, pomalidomide and dexamethasone (EloPd) proved a superior clinical benefit over Pd with manageable toxicity profile, leading to its approval in relapsed/refractory multiple myeloma (RRMM), who had received at least two prior therapies, including lenalidomide proteasome inhibitor (PI). We report here real-world experience 200 RRMMs treated EloPd 35 Italian centers outside trials. our dataset, median number lines therapy was 2, 51% cases...
Abstract Targeted immunotherapy combinations, including the anti-CD38 monoclonal antibody (MoAb) daratumumab, have shown promising results in patients with relapsed/refractory multiple myeloma (RRMM), leading to a considerable increase progression-free survival. However, large fraction of inevitably relapse. To understand this, we investigated 32 relapsed MM treated lenalidomide, and dexamethasone (Dara-Rd; NCT03848676). We conducted an integrated analysis using whole-genome sequencing (WGS)...
Abstract The ELOQUENT‐3 trial demonstrated the superiority of combination elotuzumab, pomalidomide, and dexamethasone (EloPd) in terms efficacy safety, compared to Pd relapsed/refractory multiple myeloma (RRMM), who had received at least two prior therapies, including lenalidomide a proteasome inhibitor. present study is an 18‐month follow‐up update previously published Italian real‐life RRMM cohort patients treated with EloPd. This revised analysis entered 319 accrued 41 centers. After...
Not available.
High-dose melphalan plus autologous stem-cell transplantation (ASCT) is a standard of care for transplant-eligible patients with newly diagnosed multiple myeloma (NDMM), and adequate hematopoietic (HSC) collection crucial to ensure hematologic recovery after ASCT. In this prospective, observational study we evaluated HSC mobilization granulocyte colony-stimulating factor (G-CSF), cyclophosphamide, ‘on-demand’ plerixafor (in
SUMMARY Anti-CD38 antibody therapies have transformed multiple myeloma (MM) treatment. However, a large fraction of patients inevitably relapses. To understand this, we investigated 32 relapsed MM treated with daratumumab, lenalidomide, and dexamethasone (Dara-Rd; NCT03848676 ). Whole genome sequencing (WGS) before after treatment pinpointed genomic drivers associated early progression, including RPL5 loss APOBEC mutagenesis. Flow cytometry on 202 blood samples, collected every three months...
Giulia Benevolo: received honoraria from Celgene, Novartis, Janssen, and Bristol Myers Squibb, has served on the board of directors or advisory committees for Squibb. Sara Bringhen: Amgen, GlaxoSmithKline, Sanofi, Pfizer, consultancy fees Takeda, Benedetto Bruno, Giuseppe Bertuglia Francesca Maletta have no conflicts interest to declare.
A 75-year-old Immunoglobulin A-light chain k (IgA-k) smouldering multiple myeloma patient started complaining of pain in both soles her feet which had progressively worsened and limited daily living activities (DLA). On physical examination, heels big toes were enlarged with irregular, indurated, painful, itchy nodules, some the ulcerated; periungual region right middle finger also appeared erythematosus de-epithelised (left upper panels, photographic images). No other skin lesions present....

 Background: Multiple myeloma (MM) is a malignant neoplasm characterized by the clonal expansion of plasma cells that can release monoclonal immunoglobulins (monoclonal component) or part theme. Since 2001, k and λ serum free light chains (sFLC) evaluation their ratio (rFLC) have made up laboratory analysis more sensitive precise in MM patients. The role rFLC has been widely studied discussed now it validated literature. Instead, value difference (dFLC), especially less known yet. aim...